AstraZeneca drops early head and neck cancer drug plans

LONDON (Reuters) - AstraZeneca said on Thursday it had given up on the idea of seeking an early approval of its immunotherapy drug durvalumab in head and neck cancer using mid-stage Phase II clinical trials data.